# Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma

> **NCT06824883** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 49 (estimated)

## Conditions studied

- Extranodal NK/T-cell Lymphoma

## Interventions

- **DRUG:** Immunochemotherapy

## Key facts

- **NCT ID:** NCT06824883
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-20
- **Primary completion:** 2026-05-20
- **Final completion:** 2027-05-20
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06824883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06824883, "Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06824883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*